Atea PharmaceuticalsI Ownership
| AVIR Stock | USD 3.96 0.08 1.98% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 83.4 M | Current Value 83.4 M | Avarage Shares Outstanding 68.1 M | Quarterly Volatility 19.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Atea |
Atea Stock Ownership Analysis
About 68.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.57. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atea PharmaceuticalsInc recorded a loss per share of 1.63. The entity last dividend was issued on the 9th of November 2012. The firm had 1:6 split on the 9th of November 2012. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people. For more info on Atea PharmaceuticalsInc please contact the company at 857 284 8891 or go to https://ateapharma.com.Besides selling stocks to institutional investors, Atea PharmaceuticalsI also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Atea PharmaceuticalsI's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Atea PharmaceuticalsI's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Atea PharmaceuticalsI Quarterly Liabilities And Stockholders Equity |
|
Atea PharmaceuticalsI Insider Trades History
About 10.0% of Atea PharmaceuticalsInc are currently held by insiders. Unlike Atea PharmaceuticalsI's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Atea PharmaceuticalsI's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Atea PharmaceuticalsI's insider trades
Atea Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atea PharmaceuticalsI is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atea PharmaceuticalsInc backward and forwards among themselves. Atea PharmaceuticalsI's institutional investor refers to the entity that pools money to purchase Atea PharmaceuticalsI's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2023-12-31 | 711.5 K | Federated Hermes Inc | 2023-12-31 | 595.7 K | Charles Schwab Investment Management Inc | 2023-12-31 | 584.3 K | Newtyn Management Llc | 2023-12-31 | 508.5 K | Goldman Sachs Group Inc | 2023-12-31 | 457.7 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 407.7 K | Banque Pictet & Cie Sa | 2024-03-31 | 345.1 K | Two Sigma Advisers, Llc | 2023-12-31 | 319.1 K | Nuveen Asset Management, Llc | 2023-12-31 | 291.1 K | Blackrock Inc | 2023-12-31 | 9.4 M | Ecor1 Capital, Llc | 2023-12-31 | 7 M |
Atea PharmaceuticalsInc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea PharmaceuticalsI insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea PharmaceuticalsI's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea PharmaceuticalsI insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hammond Janet Mj over a week ago Acquisition by Hammond Janet Mj of 46800 shares of Atea PharmaceuticalsI subject to Rule 16b-3 | ||
Horga Maria Arantxa over two weeks ago Acquisition by Horga Maria Arantxa of 174500 shares of Atea PharmaceuticalsI at 4.63 subject to Rule 16b-3 | ||
Corcoran Andrea over three weeks ago Disposition of 44367 shares by Corcoran Andrea of Atea PharmaceuticalsI subject to Rule 16b-3 | ||
Polsky Bruce over a month ago Acquisition by Polsky Bruce of 34025 shares of Atea PharmaceuticalsI at 23. subject to Rule 16b-3 | ||
Foster Wayne over three months ago Exercise or conversion by Foster Wayne of 33334 shares of Atea PharmaceuticalsI subject to Rule 16b-3 | ||
Duncan Barbara Gayle over six months ago Acquisition by Duncan Barbara Gayle of 33150 shares of Atea PharmaceuticalsI subject to Rule 16b-3 |
Atea PharmaceuticalsI Corporate Filings
8K | 14th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify | |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 7th of February 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Pair Trading with Atea PharmaceuticalsI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.Moving against Atea Stock
| 0.79 | BIAFW | BioAffinity Technologies | PairCorr |
| 0.7 | DOMH | Dominari Holdings | PairCorr |
| 0.65 | CI | Cigna Corp | PairCorr |
| 0.64 | LPCN | Lipocine | PairCorr |
| 0.63 | SERA | Sera Prognostics Downward Rally | PairCorr |
The ability to find closely correlated positions to Atea PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea PharmaceuticalsInc to buy it.
The correlation of Atea PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.63) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.12) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.